Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors

Drug-promoted cancers are increasingly recognized as a serious clinical problem in patients receiving BRAF inhibitory treatment. Here we report on a patient with BRAF mutant hairy cell leukemia and monoclonal B-cell lymphocytosis (MBL), who responded durably to BRAF/MEK inhibitors (BRAFi/MEKi) but e...

Descripción completa

Detalles Bibliográficos
Autores principales: Simnica, Donjete, Ittrich, Harald, Bockemeyer, Carsten, Stein, Alexander, Binder, Mascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517330/
https://www.ncbi.nlm.nih.gov/pubmed/33042833
http://dx.doi.org/10.3389/fonc.2020.540030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517330/
https://www.ncbi.nlm.nih.gov/pubmed/33042833
http://dx.doi.org/10.3389/fonc.2020.540030

Ejemplares similares